首页 > 最新文献

中华妇产科杂志最新文献

英文 中文
[Ongoing pregnancy rate with intervention and expectant therapy in patients with unexplained recurrent spontaneous abortion: a prospective multicenter cohort study]. [原因不明复发性自然流产患者干预和期待治疗的持续妊娠率:一项前瞻性多中心队列研究]。
Pub Date : 2025-04-25 DOI: 10.3760/cma.j.cn112141-20241104-00584
J X Jiang, P Y Liu, Y Liao, X M Zhong, S S Fan, L Q Feng, Y X Wang, Y Y Zhang, Q Wang

Objective: To observe the pregnancy outcomes of patients with unexplained recurrent spontaneous abortion (URSA) after interventional treatment or expectant treatment. Methods: This prospective study followed up 398 patients with recurrent spontaneous abortion from March 2017 to September 2022 in seven hospitals. Among them, 267 patients were diagnosed with URSA, including 124 patients who were initially diagnosed in the interventional treatment hospital and 143 patients who were initially diagnosed in the expectant treatment hospital. All URSA patients were followed up for 33 months. Ongoing pregnancy rates were observed as main outcome indicators. Results: A total of 127 patients became pregnant, and 107 of them had sustained pregnancies, the ongoing pregnancy rate was 84.25% (107/127). The ongoing pregnancy rate was 86.11% (31/36) in the interventional treatment group and 83.52% (76/91) in the expectant treatment group, with no significant difference (P>0.05). During the follow-up, the ongoing pregnancy rates in the interventional treatment hospital and the expectant treatment hospital were 75.71% (53/70) and 94.74% (54/57), respectively, with a significant difference (P<0.05). The ongoing pregnancy rate after interventional treatment in the interventional treatment hospital was 82.76% (24/29), which was similar to the 94.00% (47/50) after expectant treatment in the expectant treatment hospital (P>0.05). Conclusion: The ongoing pregnancy rate of interventional treatment for URSA patients has not been significantly improved, suggesting that it may not be necessary to carry out this treatment.

目的:观察不明原因复发性自然流产(URSA)患者在介入治疗或期待性治疗后的妊娠结局。方法:本前瞻性研究对2017年3月至2022年9月7家医院398例复发性自然流产患者进行随访。其中确诊URSA患者267例,其中介入性治疗医院初诊124例,期待性治疗医院初诊143例。所有URSA患者随访33个月。持续妊娠率作为主要结局指标进行观察。结果:共127例患者成功妊娠,其中持续妊娠107例,持续妊娠率为84.25%(107/127)。介入治疗组持续妊娠率为86.11%(31/36),期待治疗组持续妊娠率为83.52%(76/91),差异无统计学意义(P < 0.05)。随访期间,介入治疗医院和准产治疗医院的持续妊娠率分别为75.71%(53/70)和94.74%(54/57),差异有统计学意义(p < 0.05)。结论:介入治疗URSA患者的持续妊娠率没有明显改善,提示可能没有必要进行该治疗。
{"title":"[Ongoing pregnancy rate with intervention and expectant therapy in patients with unexplained recurrent spontaneous abortion: a prospective multicenter cohort study].","authors":"J X Jiang, P Y Liu, Y Liao, X M Zhong, S S Fan, L Q Feng, Y X Wang, Y Y Zhang, Q Wang","doi":"10.3760/cma.j.cn112141-20241104-00584","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241104-00584","url":null,"abstract":"<p><p><b>Objective:</b> To observe the pregnancy outcomes of patients with unexplained recurrent spontaneous abortion (URSA) after interventional treatment or expectant treatment. <b>Methods:</b> This prospective study followed up 398 patients with recurrent spontaneous abortion from March 2017 to September 2022 in seven hospitals. Among them, 267 patients were diagnosed with URSA, including 124 patients who were initially diagnosed in the interventional treatment hospital and 143 patients who were initially diagnosed in the expectant treatment hospital. All URSA patients were followed up for 33 months. Ongoing pregnancy rates were observed as main outcome indicators. <b>Results:</b> A total of 127 patients became pregnant, and 107 of them had sustained pregnancies, the ongoing pregnancy rate was 84.25% (107/127). The ongoing pregnancy rate was 86.11% (31/36) in the interventional treatment group and 83.52% (76/91) in the expectant treatment group, with no significant difference (<i>P</i>>0.05). During the follow-up, the ongoing pregnancy rates in the interventional treatment hospital and the expectant treatment hospital were 75.71% (53/70) and 94.74% (54/57), respectively, with a significant difference (<i>P</i><0.05). The ongoing pregnancy rate after interventional treatment in the interventional treatment hospital was 82.76% (24/29), which was similar to the 94.00% (47/50) after expectant treatment in the expectant treatment hospital (<i>P</i>>0.05). <b>Conclusion:</b> The ongoing pregnancy rate of interventional treatment for URSA patients has not been significantly improved, suggesting that it may not be necessary to carry out this treatment.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 4","pages":"289-296"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical application of transvaginal core needle biopsy for pelvic masses under finger guidance via vagino-recto-abdominal examination]. [手指引导经阴道-直腹检查经阴道芯针活检盆腔肿块的临床应用]。
Pub Date : 2025-04-25 DOI: 10.3760/cma.j.cn112141-20241021-00563
Y Q Zhang, X Y Deng, P Guan, Z H Zhang, Q L Wen, D Li

Objective: To explore the feasibility of transvaginal core needle biopsy for pelvic masses under finger guidance during a vagino-recto-abdominal examination. Methods: The clinicopathological data and follow-up information of 29 patients with pelvic masses who underwent transvaginal core needle biopsy under finger guidance during a vagino-recto-abdominal examination at Affiliated Hospital of Southwest Medical University from January 2020 to July 2024 were collected, and the safety and diagnostic accuracy of the procedure were retrospectively analyzed. Results: (1) A total of 29 patients with pelvic masses were enrolled in this study, with a median age of 50 years (range: 29-73 years), and a median tumor diameter of 3.9 cm (range: 2.7-13.3 cm). Among these patients, 7 were newly diagnosed, and 22 were follow-up. The pre-procedure disease types included 21 patients (72%, 21/29) cervical cancer, 6 patients (21%, 6/29) epithelial ovarian cancer, and 2 patients (7%, 2/29) other suspected gynecologic tumors. (2) Among 29 patients with pelvic masses, 8 cases (28%, 8/29) were diagnosed with benign diseases according to core needle biopsy pathological findings, and 1 case suggested possible residual cervical cancer in the parametrial region by contrast-enhanced magnetic resonance imaging after radical chemoradiotherapy 3 months, while the result of core needle biopsy for this patient was negative, with follow-up after 1 year revealed progression of the lesion in the right parametrial area. Another patient underwent fine-needle aspiration cytology, which suggested gastrointestinal stromal tumor, requiring differentiation from endometriosis, and core needle biopsy pathology confirmed endometriosis, with follow-up at 6 months revealed no evidence of malignancy in this patient. The remaining 6 patients with benign diagnoses had follow-up periods exceeding 1 year without imaging or clinical evidence of local lesion progression or malignancy. Among the 21 patients (72%, 21/29) diagnosed with malignant tumors by core needle biopsy, 14 cases were suspected cases of residual or recurrent cervical cancer, 6 cases had advanced ovarian cancer, and 1 case had rectal cancer metastasis, with all biopsy diagnoses being consistent with preoperative clinical findings and imaging results. The overall diagnostic accuracy of the core needle biopsy was 97% (28/29). Among the 7 newly diagnosed patients, the diagnostic accuracy was 7/7, while it was 95% (21/22) for the 22 follow-up patients, with no statistically significant difference observed between the two groups (P=1.000). (3) All 29 patients with pelvic masses successfully underwent transvaginal core needle biopsy guided by vagino-recto-abdominal examination. Among them, 28 cases (97%, 28/29) reported tolerable pain during the procedure, while 1 case (3%, 1/29) experienced transient syncope at the end of the procedure due to pain, which resolved within seconds. Vaginal bleeding exceeding 50

目的:探讨手指引导下经阴道芯针活检盆腔肿块的可行性。方法:收集2020年1月至2024年7月西南医科大学附属医院阴道直腹检查期间手指引导下经阴道芯针活检29例盆腔肿块患者的临床病理资料及随访资料,回顾性分析该方法的安全性及诊断准确性。结果:(1)本研究共纳入29例盆腔肿块患者,中位年龄50岁(范围29-73岁),中位肿瘤直径3.9 cm(范围2.7-13.3 cm)。其中新诊断7例,随访22例。术前疾病类型包括宫颈癌21例(72%,21/29),上皮性卵巢癌6例(21%,6/29),其他疑似妇科肿瘤2例(7%,2/29)。(2) 29例盆腔肿块患者中,8例(28%,8/29)经核针活检病理诊断为良性病变,其中1例患者在根治性放化疗3个月后经磁共振造影提示参数区可能残留宫颈癌,该患者核针活检结果为阴性,1年后随访显示右侧参数区病变进展。另一例患者行细针穿刺细胞学检查提示胃肠道间质瘤,需与子宫内膜异位症鉴别,芯针活检病理证实子宫内膜异位症,随访6个月未见恶性肿瘤。其余6例诊断为良性的患者随访时间超过1年,无影像学或局部病变进展或恶性肿瘤的临床证据。在21例(72%,21/29)经芯针活检确诊为恶性肿瘤的患者中,14例疑似宫颈癌残留或复发,6例为晚期卵巢癌,1例为直肠癌转移,活检诊断均与术前临床表现及影像学结果一致。核心穿刺活检的总体诊断准确率为97%(28/29)。7例新诊断患者的诊断准确率为7/7,而22例随访患者的诊断准确率为95%(21/22),两组比较差异无统计学意义(P=1.000)。(3) 29例盆腔肿块患者均成功行阴道直腹检查引导下经阴道芯针活检。其中28例(97%,28/29)报告术中疼痛可忍受,1例(3%,1/29)在手术结束时因疼痛出现一过性晕厥,数秒内消失。宫颈旁组织取样过程中有3例(10%,3/29)患者阴道出血超过50 ml,出血量最大为150 ml,采用阴道填塞术成功控制出血。核心穿刺活检过程中不良事件的总发生率为14%(4/29)。结论:阴道直腹检查指导下经阴道芯针活检盆腔肿块是一种简便、安全、准确的诊断方法,适用于妇科恶性肿瘤、怀疑盆腔肿块转移的非妇科恶性肿瘤及其他盆腔良性病变患者。
{"title":"[Clinical application of transvaginal core needle biopsy for pelvic masses under finger guidance via vagino-recto-abdominal examination].","authors":"Y Q Zhang, X Y Deng, P Guan, Z H Zhang, Q L Wen, D Li","doi":"10.3760/cma.j.cn112141-20241021-00563","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241021-00563","url":null,"abstract":"<p><p><b>Objective:</b> To explore the feasibility of transvaginal core needle biopsy for pelvic masses under finger guidance during a vagino-recto-abdominal examination. <b>Methods:</b> The clinicopathological data and follow-up information of 29 patients with pelvic masses who underwent transvaginal core needle biopsy under finger guidance during a vagino-recto-abdominal examination at Affiliated Hospital of Southwest Medical University from January 2020 to July 2024 were collected, and the safety and diagnostic accuracy of the procedure were retrospectively analyzed. <b>Results:</b> (1) A total of 29 patients with pelvic masses were enrolled in this study, with a median age of 50 years (range: 29-73 years), and a median tumor diameter of 3.9 cm (range: 2.7-13.3 cm). Among these patients, 7 were newly diagnosed, and 22 were follow-up. The pre-procedure disease types included 21 patients (72%, 21/29) cervical cancer, 6 patients (21%, 6/29) epithelial ovarian cancer, and 2 patients (7%, 2/29) other suspected gynecologic tumors. (2) Among 29 patients with pelvic masses, 8 cases (28%, 8/29) were diagnosed with benign diseases according to core needle biopsy pathological findings, and 1 case suggested possible residual cervical cancer in the parametrial region by contrast-enhanced magnetic resonance imaging after radical chemoradiotherapy 3 months, while the result of core needle biopsy for this patient was negative, with follow-up after 1 year revealed progression of the lesion in the right parametrial area. Another patient underwent fine-needle aspiration cytology, which suggested gastrointestinal stromal tumor, requiring differentiation from endometriosis, and core needle biopsy pathology confirmed endometriosis, with follow-up at 6 months revealed no evidence of malignancy in this patient. The remaining 6 patients with benign diagnoses had follow-up periods exceeding 1 year without imaging or clinical evidence of local lesion progression or malignancy. Among the 21 patients (72%, 21/29) diagnosed with malignant tumors by core needle biopsy, 14 cases were suspected cases of residual or recurrent cervical cancer, 6 cases had advanced ovarian cancer, and 1 case had rectal cancer metastasis, with all biopsy diagnoses being consistent with preoperative clinical findings and imaging results. The overall diagnostic accuracy of the core needle biopsy was 97% (28/29). Among the 7 newly diagnosed patients, the diagnostic accuracy was 7/7, while it was 95% (21/22) for the 22 follow-up patients, with no statistically significant difference observed between the two groups (<i>P</i>=1.000). (3) All 29 patients with pelvic masses successfully underwent transvaginal core needle biopsy guided by vagino-recto-abdominal examination. Among them, 28 cases (97%, 28/29) reported tolerable pain during the procedure, while 1 case (3%, 1/29) experienced transient syncope at the end of the procedure due to pain, which resolved within seconds. Vaginal bleeding exceeding 50","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 4","pages":"297-303"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Nomogram based on clinical and DCE-MRI characteristics for predicting the depth of myometrial invasion and grade of endometrioid endometrial carcinoma]. [基于临床和DCE-MRI特征预测子宫内膜浸润深度和子宫内膜样癌分级的Nomogram]。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20241211-00658
X L Ma, S Q Cai, J W Qiang, G F Zhang, J J Zhou, M S Zeng, X J Ren, R Jiang, M H Shen

Objective: To investigate the feasibility and value of nomogram based on base line clinical and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) characteristics for pretreatment predicting the depth of myometrial invasion and tumor grade of endometrioid endometrial carcinoma (EEC). Methods: Preoperative baseline clinical characteristics and DCE-MRI characteristics of 194 EEC patients were prospectively collected at Obstetrics and Gynecology Hospital, Fudan University from October 2020 to January 2022 and used as a training set. Univariate analysis was conducted to compare baseline clinical characteristics and DCE-MRI quantitative parameters [including tumor volume, and mean, median, and standard deviation of volume transfer constant (Ktrans), rate constant (Kep), extravascular extracellular volume fraction (Ve), and initial area under the enhancement curve (iAUC)] between patients with deep myometrial invasion (DMI) and those with superficial myometrial invasion (SMI), as well as between high-grade and low-grade EEC. Multivariate logistics regression analysis was used to identify independent predictors for the construction of nomogram. An independent external testing set comprising 127 EEC patients was retrospectively collected from Zhongshan Hospital, Fudan University and Zhongshan Hospital, Fudan University (Xiamen Branch). The area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA) were used for evaluating the model's predictive performance and clinical net benefit, respectively. Results: (1) The depth of myometrial invasion: univariate analysis showed that in the training set, the EEC patients with DMI differed significantly from those with SMI in clinical characteristics including higher proportion of postmenopausal state and overweight [body mass index (BMI)≥25 kg/m²], and abnormal levels of serum cancer antigen (CA)125, CA199, and human epididymis protein 4 (HE4), and in DCE-MRI quantitative parameters including tumor volume, and median, mean, and standard deviation of Ktrans, median of Ve, as well as median, mean, and standard deviation of iAUC (all P<0.05). Multivariate analysis showed that the patient's menstrual status, BMI, CA199, tumor volume, and mean of iAUC were independent predictors of the depth of myometrial invasion, and constructed the nomogram (recorded as Nomogram_1), achieving an AUC of 0.861 (95%CI: 0.803-0.919) in the training set. In the independent external testing set, the AUC was 0.876 (95%CI: 0.815-0.938), with corresponding sensitivity of 82.0%, specificity of 80.7%, accuracy of 81.1%, positive predictive value (PPV) of 65.3%, and negative predictive value (NPV) of 91.0% for predicting DMI. (2) The EEC grade: univariate analysis showed that in the training set, high-grade EEC patients differed significantly from low-grade EEC in

目的:探讨基于基线临床和动态磁共振成像(DCE-MRI)特征的nomogram预处理预测子宫内膜样子宫内膜癌(EEC)侵袭肌层深度及肿瘤分级的可行性和价值。方法:前瞻性收集2020年10月至2022年1月复旦大学附属妇产科医院194例脑电图患者的术前基线临床特征及DCE-MRI特征,作为训练集。采用单因素分析比较深部肌层浸润(DMI)患者和浅表肌层浸润(SMI)患者以及高级别和低级别EEC患者的基线临床特征和DCE-MRI定量参数[包括肿瘤体积、体积转移常数(Ktrans)、速率常数(Kep)、血管外细胞外体积分数(Ve)和初始增强曲线下面积(iAUC)的平均值、中位数和标准差]以及肿瘤体积。采用多元logistic回归分析确定独立预测因子,构建模态图。回顾性收集复旦大学附属中山医院和复旦大学附属中山医院厦门分院127例脑电图患者的独立外部检测数据。采用受试者工作特征曲线下面积(AUC)和决策曲线分析(DCA)分别评价模型的预测性能和临床净收益。结果:(1)肌层浸润深度:单因素分析显示,在训练集中,EEC DMI患者的临床特征,包括绝经后状态和超重比例较高[体重指数(BMI)≥25 kg/m²],血清癌抗原(CA)125、CA199和人附睾蛋白4 (HE4)水平异常,DCE-MRI定量参数,包括肿瘤体积,Ktrans的中位数、平均值和标准差,Ve的中位数,以及中位数。P199、肿瘤体积、iAUC均值均为肌层浸润深度的独立预测因子,并构建nomogram(记为Nomogram_1),在训练集中获得了0.861 (95%CI: 0.803 ~ 0.919)的AUC。在独立的外部检测集中,AUC为0.876 (95%CI: 0.815 ~ 0.938),预测DMI的敏感性为82.0%,特异性为80.7%,准确性为81.1%,阳性预测值(PPV)为65.3%,阴性预测值(NPV)为91.0%。(2) EEC等级:单因素分析显示,在训练集中,高级别EEC患者与低级别EEC患者在患者年龄、绝经后状态和超重比例、血清CA125异常水平等临床特征,以及DCE-MRI定量参数(肿瘤体积、Ktrans的中位数、平均值、标准差、Ve的中位数和平均值、中位数、平均值、和iAUC的标准差(所有Pe都作为EEC等级的独立预测因子,并构建了nomogram(记为Nomogram_2),在训练集中获得了0.845 (95%CI: 0.786-0.893)的AUC。而在外部检测集中,AUC为0.819 (95%CI: 0.744 ~ 0.894),预测高级别EEC的敏感性为72.4%,特异性为72.4%,准确性为72.4%,PPV为43.8%,NPV为89.9%。(3) DCA曲线显示Nomogram_1和Nomogram_2在较宽的阈值概率范围内均具有明显的临床净效益。结论:基于临床预处理和DCE-MRI特征的nomogram无创预测肌层浸润深度和脑电图分级,为临床管理决策提供有价值的参考信息。
{"title":"[Nomogram based on clinical and DCE-MRI characteristics for predicting the depth of myometrial invasion and grade of endometrioid endometrial carcinoma].","authors":"X L Ma, S Q Cai, J W Qiang, G F Zhang, J J Zhou, M S Zeng, X J Ren, R Jiang, M H Shen","doi":"10.3760/cma.j.cn112141-20241211-00658","DOIUrl":"10.3760/cma.j.cn112141-20241211-00658","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the feasibility and value of nomogram based on base line clinical and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) characteristics for pretreatment predicting the depth of myometrial invasion and tumor grade of endometrioid endometrial carcinoma (EEC). <b>Methods:</b> Preoperative baseline clinical characteristics and DCE-MRI characteristics of 194 EEC patients were prospectively collected at Obstetrics and Gynecology Hospital, Fudan University from October 2020 to January 2022 and used as a training set. Univariate analysis was conducted to compare baseline clinical characteristics and DCE-MRI quantitative parameters [including tumor volume, and mean, median, and standard deviation of volume transfer constant (K<sup>trans</sup>), rate constant (K<sub>ep</sub>), extravascular extracellular volume fraction (V<sub>e</sub>), and initial area under the enhancement curve (iAUC)] between patients with deep myometrial invasion (DMI) and those with superficial myometrial invasion (SMI), as well as between high-grade and low-grade EEC. Multivariate logistics regression analysis was used to identify independent predictors for the construction of nomogram. An independent external testing set comprising 127 EEC patients was retrospectively collected from Zhongshan Hospital, Fudan University and Zhongshan Hospital, Fudan University (Xiamen Branch). The area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA) were used for evaluating the model's predictive performance and clinical net benefit, respectively. <b>Results:</b> (1) The depth of myometrial invasion: univariate analysis showed that in the training set, the EEC patients with DMI differed significantly from those with SMI in clinical characteristics including higher proportion of postmenopausal state and overweight [body mass index (BMI)≥25 kg/m²], and abnormal levels of serum cancer antigen (CA)<sub>125</sub>, CA<sub>199</sub>, and human epididymis protein 4 (HE4), and in DCE-MRI quantitative parameters including tumor volume, and median, mean, and standard deviation of K<sup>trans</sup>, median of V<sub>e</sub>, as well as median, mean, and standard deviation of iAUC (all <i>P</i><0.05). Multivariate analysis showed that the patient's menstrual status, BMI, CA<sub>199</sub>, tumor volume, and mean of iAUC were independent predictors of the depth of myometrial invasion, and constructed the nomogram (recorded as Nomogram_1), achieving an AUC of 0.861 (95%<i>CI</i>: 0.803-0.919) in the training set. In the independent external testing set, the AUC was 0.876 (95%<i>CI</i>: 0.815-0.938), with corresponding sensitivity of 82.0%, specificity of 80.7%, accuracy of 81.1%, positive predictive value (PPV) of 65.3%, and negative predictive value (NPV) of 91.0% for predicting DMI. (2) The EEC grade: univariate analysis showed that in the training set, high-grade EEC patients differed significantly from low-grade EEC in ","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"202-215"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Safety evaluation of Chinese-made robot-assisted laparoscopic sacrocolpopexy: a single-center, small-scale, single-arm study]. [国产机器人辅助腹腔镜骶colpop固定术的安全性评价:单中心、小规模、单臂研究]。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20241214-00670
L Zhang, X X Wang, X Q Wang, Q Y Zhang, L H Zhang, Y Huang, Y Lu

Objective: To describe the safety of using the Chinese-made robotic laparoscopic surgery system for laparoscopic sacrocolpopexy in the treatment of severe pelvic organ prolapse. Methods: A pilot descriptive clinical study was conducted, enrolling 16 severe pelvic organ prolapse patients at Peking University First Hospital from April 2023 to January 2024. Patients who consented to participate in this study underwent laparoscopic sacrocolpopexy for severe pelvic organ prolapse using Chinese-made robotic laparoscopic surgery system. Preoperative clinical basic data and perioperative data of the patients were collected, summarizing the data on perioperative bleeding and complications, and reviewed the surgical learning experience. The evaluation indicators related to the learning experience included: (1) efficiency evaluation: including equipment docking time, total surgery time, suturing time, mechanical arm operation time and hysterectomy time, which were timed and recorded during surgery; (2) equipment operability evaluation: including equipment operation task load assessment and intraoperative operation feeling score. The cumulative sum analysis method was used to quantify surgery time and fit the learning curve. Results: Sixteen patients were successfully enrolled and underwent surgery, including total hysterectomy with bilateral salpingo-oophorectomy or salpingectomy plus sacrocolpopexy, or sacrocolpopexy alone (for one case without uterus). The age of 16 cases was (56.7±7.6) years (ranged from 44 to 67 years), with body mass index of (25.4±2.5) kg/m². Concurrent procedures included anterior vaginal wall repair in 12 cases (12/16), posterior vaginal wall repair in 13 cases (13/16), tension-free vaginal tape obturator system in 1 case (1/16), and recto-uterine pouch hernia repair in 4 cases (4/16). The total surgery time was (355.8±91.1) minutes, with docking time at (6.7±4.9) minutes, robotic operative time at (267.6±81.4) minutes, robotic suturing time at (155.6±53.9) minutes, and hysterectomy time at (112.0±45.3) minutes. Learning curve analysis revealed inflection points at 6 cases for total surgery time (P<0.001, R²=0.944) and robotic operative time (P<0.001, R²=0.982), 5 cases for docking time (P<0.001, R²=0.989), and 6 cases for robotic suturing time (P<0.001, R²=0.907). Hysterectomy time had an inflection point at 5 cases (P=0.023, R²=0.700). Median blood loss was 30 ml (range: 10-1 000 ml), with severe bleeding in one patient (1/16). No conversions to open surgery or laparoscopy occurred, and no severe perioperative or postoperative complications were reported. Conclusion: The Chinese-made robotic laparoscopic surgery system demonstrates excellent short-time safety and ease of operation for laparoscopic sacrocolpopexy.

目的:探讨国产机器人腹腔镜手术系统在腹腔镜骶colpop固定术治疗严重盆腔器官脱垂中的安全性。方法:对2023年4月至2024年1月北京大学第一医院重症盆腔器官脱垂患者16例进行描述性临床试验。同意参加本研究的患者采用国产机器人腹腔镜手术系统行腹腔镜骶colpop固定术治疗严重盆腔器官脱垂。收集患者术前临床基础资料及围手术期资料,总结围手术期出血及并发症资料,复习手术学习经验。与学习经验相关的评价指标包括:(1)效率评价:包括设备对接时间、手术总时间、缝合时间、机械臂操作时间、子宫切除时间,术中计时并记录;(2)设备可操作性评价:包括设备操作任务负荷评价和术中操作感受评分。采用累积和分析法量化手术时间,拟合学习曲线。结果:16例患者成功入组并行手术,包括全子宫切除+双侧输卵管-卵巢切除术或输卵管切除+骶阴道固定术,或单独骶阴道固定术(1例无子宫)。16例患者年龄(56.7±7.6)岁(44 ~ 67岁),体重指数(25.4±2.5)kg/m²。同期行阴道前壁修复12例(12/16),阴道后壁修复13例(13/16),阴道无张力带闭孔系统修复1例(1/16),直肠-子宫袋疝修补4例(4/16)。手术总时间为(355.8±91.1)分钟,其中对接时间为(6.7±4.9)分钟,机器人手术时间为(267.6±81.4)分钟,机器人缝合时间为(155.6±53.9)分钟,子宫切除时间为(112.0±45.3)分钟。学习曲线分析显示,总手术时间(PR²=0.944)和机器人手术时间(PR²=0.982)6例,对接时间(PR²=0.989)5例,机器人缝合时间(PR²=0.907)6例出现拐点。子宫切除术时间在5例出现拐点(P=0.023, R²=0.700)。中位失血量为30 ml(范围:10-1 000 ml), 1例患者严重出血(1/16)。无转开腹手术或腹腔镜手术发生,无严重围手术期或术后并发症报道。结论:国产机器人腹腔镜手术系统对腹腔镜骶髋固定术具有较好的短时间安全性和易操作性。
{"title":"[Safety evaluation of Chinese-made robot-assisted laparoscopic sacrocolpopexy: a single-center, small-scale, single-arm study].","authors":"L Zhang, X X Wang, X Q Wang, Q Y Zhang, L H Zhang, Y Huang, Y Lu","doi":"10.3760/cma.j.cn112141-20241214-00670","DOIUrl":"10.3760/cma.j.cn112141-20241214-00670","url":null,"abstract":"<p><p><b>Objective:</b> To describe the safety of using the Chinese-made robotic laparoscopic surgery system for laparoscopic sacrocolpopexy in the treatment of severe pelvic organ prolapse. <b>Methods:</b> A pilot descriptive clinical study was conducted, enrolling 16 severe pelvic organ prolapse patients at Peking University First Hospital from April 2023 to January 2024. Patients who consented to participate in this study underwent laparoscopic sacrocolpopexy for severe pelvic organ prolapse using Chinese-made robotic laparoscopic surgery system. Preoperative clinical basic data and perioperative data of the patients were collected, summarizing the data on perioperative bleeding and complications, and reviewed the surgical learning experience. The evaluation indicators related to the learning experience included: (1) efficiency evaluation: including equipment docking time, total surgery time, suturing time, mechanical arm operation time and hysterectomy time, which were timed and recorded during surgery; (2) equipment operability evaluation: including equipment operation task load assessment and intraoperative operation feeling score. The cumulative sum analysis method was used to quantify surgery time and fit the learning curve. <b>Results:</b> Sixteen patients were successfully enrolled and underwent surgery, including total hysterectomy with bilateral salpingo-oophorectomy or salpingectomy plus sacrocolpopexy, or sacrocolpopexy alone (for one case without uterus). The age of 16 cases was (56.7±7.6) years (ranged from 44 to 67 years), with body mass index of (25.4±2.5) kg/m². Concurrent procedures included anterior vaginal wall repair in 12 cases (12/16), posterior vaginal wall repair in 13 cases (13/16), tension-free vaginal tape obturator system in 1 case (1/16), and recto-uterine pouch hernia repair in 4 cases (4/16). The total surgery time was (355.8±91.1) minutes, with docking time at (6.7±4.9) minutes, robotic operative time at (267.6±81.4) minutes, robotic suturing time at (155.6±53.9) minutes, and hysterectomy time at (112.0±45.3) minutes. Learning curve analysis revealed inflection points at 6 cases for total surgery time (<i>P</i><0.001, <i>R</i>²=0.944) and robotic operative time (<i>P</i><0.001, <i>R</i>²=0.982), 5 cases for docking time (<i>P</i><0.001, <i>R</i>²=0.989), and 6 cases for robotic suturing time (<i>P</i><0.001, <i>R</i>²=0.907). Hysterectomy time had an inflection point at 5 cases (<i>P</i>=0.023, <i>R</i>²=0.700). Median blood loss was 30 ml (range: 10-1 000 ml), with severe bleeding in one patient (1/16). No conversions to open surgery or laparoscopy occurred, and no severe perioperative or postoperative complications were reported. <b>Conclusion:</b> The Chinese-made robotic laparoscopic surgery system demonstrates excellent short-time safety and ease of operation for laparoscopic sacrocolpopexy.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"183-192"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Carrier screening and prenatal diagnosis analysis of high-risk cases in 3 044 preconception and early pregnancy couples]. 3 044例孕前早孕夫妇携带者筛查及高危病例产前诊断分析
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20240928-00531
X L Fu, W Hou, M L Zhang, X X Xie, Y Meng, H H Zhou, Q D Zhao, J L Hu, G P Mo, Y P Lu
<p><p><b>Objective:</b> To carry out carrier screening among people of childbearing age, detect the pathogenic genes of monogenic genetic diseases and analyze the carrier status of pathogenic variants, so as to provide fertility guidance and intervention measures for high-risk families. <b>Methods:</b> From August 2022 to August 2023, 1 533 families of childbearing age who met the criteria were recruited in the Chinese PLA General Hospital, including a total of 3 044 subjects. According to the standard enrollment procedure, 223 genes (197 autosomal recessive genes and 26 X-linked genes) of the subjects were tested. According to the screening results, genetic counseling and fertility guidance were provided to the subjects. Invasive prenatal diagnosis was performed for high-risk couples (both couples being carriers of the same autosomal recessive disease gene or the woman was a carrier of X-linked disease gene), and their pregnancy pattern, outcome and offspring phenotype were followed up. <b>Results:</b> (1) A total of 3 044 cases from 1 511 couples and women of childbearing age from 22 families were included for carrier screening. Totally 1 503 families chose simultaneous screening and 30 families chose sequential screening out of the 1 533 families. Among the 3 044 subjects, 1 603 individuals carried at least one pathogenic or likely pathogenic variant, and the overall carrier rate was 52.66% (1 603/3 044). A total of 2 292 pathogenic or likely pathogenic variants were detected, and 0.75 variants (2 292/3 044) were detected per capita. (2) The three genes with the highest carrier rates were GJB2 (8.67%, 264/3 044), CYP21A2 (3.19%, 97/3 044) and PAH (3.09%, 94/3 044). There were 32 genes with a carrier rate ≥1/200, 17 genes with a carrier rate ≥1/100, and 7 genes with a carrier rate ≥1/50. (3) Thirty-eight high-risk families were identified. After excluding G6PD gene mutation, there were 33 high-risk families, of which 25 couples were carriers of the same autosomal recessive gene, 9 women were carriers of X-linked gene, and 1 family was double high-risk couple with both autosomal recessive and X-linked gene. After further excluding the GJB2 c.109G>A mutation, 21 high-risk families were identified. Preimplantation genetic testing for monogenic disease was performed in 12 families after genetic counseling. Prenatal diagnosis was completed in 4 out of 5 high-risk families who conceived naturally. Two fetuses carried the parental variants and terminated the pregnancy, one fetus did not carry the parental variants but was induced due to trisomy 21 syndrome, and one fetus was a carrier of congenital disorders of glycosylation type 1a. <b>Conclusions:</b> Carrier screening effectively identifies high-risk genetic disease families and provides reproductive guidance to prevent the birth of affected children. However, establishing multidisciplinary team is essential for managing complex cases. Implementation should prioritize prenatal institutions with gen
目的:在育龄人群中开展携带者筛查,检测单基因遗传病致病基因,分析致病变异的携带者状况,为高危家庭提供生育指导和干预措施。方法:于2022年8月至2023年8月在中国人民解放军总医院招募符合标准的育龄家庭1 533户,共3 044名受试者。按照标准入组程序,检测223个基因(常染色体隐性基因197个,x连锁基因26个)。根据筛查结果对受试者进行遗传咨询和生育指导。对高危夫妇(双方携带同一常染色体隐性遗传病基因或女方携带x连锁遗传病基因)进行有创产前诊断,随访妊娠模式、结局及子代表型。结果:(1)共纳入3 044例1 511对夫妇和22个家庭的育龄妇女进行带菌者筛查。在1533个家庭中,有1503个家庭选择同时筛查,30个家庭选择顺序筛查。3 044例中,1 603人携带至少一种致病或可能致病变异,总带菌率为52.66%(1 603/3 044)。共检出致病性或可能致病性变异2 292个,人均检出变异0.75个(2 292/3 044个)。(2)携带率最高的基因为GJB2(8.67%, 264/3 044)、CYP21A2(3.19%, 97/3 044)和PAH(3.09%, 94/3 044)。携带率≥1/200的基因有32个,携带率≥1/100的基因有17个,携带率≥1/50的基因有7个。(3)确定38个高危家庭。排除G6PD基因突变后,共有33个高危家族,其中25对夫妻为同一常染色体隐性基因携带者,9名女性为x连锁基因携带者,1对家庭为常染色体隐性基因和x连锁基因双高危夫妇。在进一步排除GJB2 c.109G>A突变后,鉴定出21个高危家族。在遗传咨询后,对12个家庭进行单基因疾病植入前基因检测。5个自然受孕的高危家庭中有4个完成了产前诊断。两个胎儿携带亲本变异终止妊娠,一个胎儿没有携带亲本变异,但由于21三体综合征而诱导,一个胎儿携带先天性糖基化1a型疾病。结论:携带者筛查可有效识别遗传病高危家族,为预防患儿出生提供生殖指导。然而,建立多学科团队是管理复杂病例的必要条件。实施时应优先考虑具有遗传咨询或单基因疾病诊断专业知识的产前机构或已建立的转诊网络。
{"title":"[Carrier screening and prenatal diagnosis analysis of high-risk cases in 3 044 preconception and early pregnancy couples].","authors":"X L Fu, W Hou, M L Zhang, X X Xie, Y Meng, H H Zhou, Q D Zhao, J L Hu, G P Mo, Y P Lu","doi":"10.3760/cma.j.cn112141-20240928-00531","DOIUrl":"10.3760/cma.j.cn112141-20240928-00531","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To carry out carrier screening among people of childbearing age, detect the pathogenic genes of monogenic genetic diseases and analyze the carrier status of pathogenic variants, so as to provide fertility guidance and intervention measures for high-risk families. &lt;b&gt;Methods:&lt;/b&gt; From August 2022 to August 2023, 1 533 families of childbearing age who met the criteria were recruited in the Chinese PLA General Hospital, including a total of 3 044 subjects. According to the standard enrollment procedure, 223 genes (197 autosomal recessive genes and 26 X-linked genes) of the subjects were tested. According to the screening results, genetic counseling and fertility guidance were provided to the subjects. Invasive prenatal diagnosis was performed for high-risk couples (both couples being carriers of the same autosomal recessive disease gene or the woman was a carrier of X-linked disease gene), and their pregnancy pattern, outcome and offspring phenotype were followed up. &lt;b&gt;Results:&lt;/b&gt; (1) A total of 3 044 cases from 1 511 couples and women of childbearing age from 22 families were included for carrier screening. Totally 1 503 families chose simultaneous screening and 30 families chose sequential screening out of the 1 533 families. Among the 3 044 subjects, 1 603 individuals carried at least one pathogenic or likely pathogenic variant, and the overall carrier rate was 52.66% (1 603/3 044). A total of 2 292 pathogenic or likely pathogenic variants were detected, and 0.75 variants (2 292/3 044) were detected per capita. (2) The three genes with the highest carrier rates were GJB2 (8.67%, 264/3 044), CYP21A2 (3.19%, 97/3 044) and PAH (3.09%, 94/3 044). There were 32 genes with a carrier rate ≥1/200, 17 genes with a carrier rate ≥1/100, and 7 genes with a carrier rate ≥1/50. (3) Thirty-eight high-risk families were identified. After excluding G6PD gene mutation, there were 33 high-risk families, of which 25 couples were carriers of the same autosomal recessive gene, 9 women were carriers of X-linked gene, and 1 family was double high-risk couple with both autosomal recessive and X-linked gene. After further excluding the GJB2 c.109G&gt;A mutation, 21 high-risk families were identified. Preimplantation genetic testing for monogenic disease was performed in 12 families after genetic counseling. Prenatal diagnosis was completed in 4 out of 5 high-risk families who conceived naturally. Two fetuses carried the parental variants and terminated the pregnancy, one fetus did not carry the parental variants but was induced due to trisomy 21 syndrome, and one fetus was a carrier of congenital disorders of glycosylation type 1a. &lt;b&gt;Conclusions:&lt;/b&gt; Carrier screening effectively identifies high-risk genetic disease families and provides reproductive guidance to prevent the birth of affected children. However, establishing multidisciplinary team is essential for managing complex cases. Implementation should prioritize prenatal institutions with gen","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"161-170"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Advances of targeting EZH2 in gynecological malignancies]. 【EZH2靶向治疗妇科恶性肿瘤的研究进展】。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20240815-00455
Y S Jiao, C Li, Y Xiang
{"title":"[Advances of targeting EZH2 in gynecological malignancies].","authors":"Y S Jiao, C Li, Y Xiang","doi":"10.3760/cma.j.cn112141-20240815-00455","DOIUrl":"10.3760/cma.j.cn112141-20240815-00455","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"236-240"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effects of continuous positive airway pressure on maternal and neonatal outcomes in pregnant women with obstructive sleep apnea syndrome]. [持续气道正压通气对阻塞性睡眠呼吸暂停综合征孕妇母婴结局的影响]。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20240808-00444
Z L Tu, R Bai, L Y Zhang, J Y Wang, S D Hong, J J Yang, J Wei, Y Wang, Y N Liu, X S Dong, F Han, G L Liu
<p><p><b>Objective:</b> To analyze the effect of continuous positive airway pressure (CPAP) on maternal and neonatal outcomes in pregnant women with obstructive sleep apnea syndrome (OSAS), especially on the incidence of hypertensive disorder in pregnancy (HDP) in women with moderate to severe OSAS. <b>Methods:</b> A total of 180 pregnant women with OSAS who were diagnosed through sleep monitoring during pregnancy due to high-risk factors of OSAS and registered in Peking University People's Hospital from January 2021 to May 2024 were selected as the study subjects. Clinical data were collected from medical records for retrospective analysis. According to whether they received standardized treatment with CPAP, they were divided into the CPAP treatment group (42 cases) and the control group (138 cases). The CPAP treatment group consisted of 9 pregnant women with moderate to severe OSAS, while the control group consisted of 34 pregnant women with moderate to severe OSAS. The maternal and neonatal outcomes, the incidence of HDP, placental weight after delivery and placental weight/neonatal birth weight ratio were compared between the two groups. <b>Results:</b> (1) The average gestational age of pregnant women in the CPAP treatment group was higher than that in the control group [(38.7±1.0) vs (38.0±1.4) weeks], the proportion of infants small for gestational age (SGA) in the CPAP treatment group was lower [0 (0/42) vs 12.3% (17/138)], and the birth weight of infants in the CPAP treatment group was bigger [(3 396±475) vs (3 082±710) g); the differences between the two groups were statistically significant (all <i>P</i><0.05). There were no significant differences between the CPAP treatment group and the control group in terms of delivery mode, rates of postpartum hemorrhage and preterm birth, umbilical artery blood gas analysis pH<7.1, lactate≥6.0 mmol/L, base excess<-12.0 mmol/L and the incidence of gestational diabetes mellitus and HDP (all <i>P</i>>0.05). (2) The placental weight of the CPAP treatment group was significantly lower than that of the control group [(554.0±70.6) vs (615.7±119.1) g], the placental weight/newborn birth weight ratio of the CPAP treatment group was significantly lower than that of the control group (median: 0.17 vs 0.19), and the differences were statistically significant (all <i>P</i><0.05). (3) The incidence of HDP in pregnant women with moderate to severe OSAS in the CPAP treatment group was lower than that in the control group [1/9 vs 61.8% (21/34)], and the difference was statistically significant (<i>P</i><0.05). <b>Conclusions:</b> CPAP treatment could prolong the gestational age in pregnant women with OSAS, reduce the incidence of SGA, increase the birth weight of infants, and reduce the incidence of HDP in pregnant women with moderate to severe OSAS, and is worth promoting in clinical practice. The improvement of neonatal outcomes by CPAP treatment is closely related to the placenta, which is worthy of further ex
目的:分析持续气道正压通气(CPAP)对阻塞性睡眠呼吸暂停综合征(OSAS)孕妇孕产妇及新生儿结局的影响,特别是对中重度阻塞性睡眠呼吸暂停综合征(OSAS)孕妇妊娠期高血压疾病(HDP)发生率的影响。方法:选择2021年1月至2024年5月在北京大学人民医院登记的180例经孕期睡眠监测诊断为OSAS高危因素的OSAS孕妇作为研究对象。从病历中收集临床资料进行回顾性分析。根据是否接受CPAP规范化治疗分为CPAP治疗组(42例)和对照组(138例)。CPAP治疗组为9例中至重度OSAS孕妇,对照组为34例中至重度OSAS孕妇。比较两组产妇及新生儿结局、HDP发生率、产后胎盘重量及胎盘重量/新生儿出生体重比。结果:(1)CPAP治疗组孕妇平均胎龄高于对照组[(38.7±1.0)vs(38.0±1.4)周],小于胎龄儿(SGA)比例低于对照组[0 (0/42)vs 12.3%(17/138)],新生儿出生体重大于对照组[(3 396±475)vs(3 082±710)g);两组间差异均有统计学意义(p < 0.05)。(2) CPAP治疗组胎盘重量显著低于对照组[(554.0±70.6)vs(615.7±119.1)g], CPAP治疗组胎盘重量/新生儿体重比显著低于对照组(中位数:0.17 vs 0.19),差异均有统计学意义(均ppp)。CPAP治疗可以延长OSAS孕妇的胎龄,降低SGA的发生率,增加婴儿出生体重,降低中重度OSAS孕妇HDP的发生率,值得临床推广。CPAP治疗对新生儿预后的改善与胎盘密切相关,值得进一步探讨。
{"title":"[Effects of continuous positive airway pressure on maternal and neonatal outcomes in pregnant women with obstructive sleep apnea syndrome].","authors":"Z L Tu, R Bai, L Y Zhang, J Y Wang, S D Hong, J J Yang, J Wei, Y Wang, Y N Liu, X S Dong, F Han, G L Liu","doi":"10.3760/cma.j.cn112141-20240808-00444","DOIUrl":"10.3760/cma.j.cn112141-20240808-00444","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To analyze the effect of continuous positive airway pressure (CPAP) on maternal and neonatal outcomes in pregnant women with obstructive sleep apnea syndrome (OSAS), especially on the incidence of hypertensive disorder in pregnancy (HDP) in women with moderate to severe OSAS. &lt;b&gt;Methods:&lt;/b&gt; A total of 180 pregnant women with OSAS who were diagnosed through sleep monitoring during pregnancy due to high-risk factors of OSAS and registered in Peking University People's Hospital from January 2021 to May 2024 were selected as the study subjects. Clinical data were collected from medical records for retrospective analysis. According to whether they received standardized treatment with CPAP, they were divided into the CPAP treatment group (42 cases) and the control group (138 cases). The CPAP treatment group consisted of 9 pregnant women with moderate to severe OSAS, while the control group consisted of 34 pregnant women with moderate to severe OSAS. The maternal and neonatal outcomes, the incidence of HDP, placental weight after delivery and placental weight/neonatal birth weight ratio were compared between the two groups. &lt;b&gt;Results:&lt;/b&gt; (1) The average gestational age of pregnant women in the CPAP treatment group was higher than that in the control group [(38.7±1.0) vs (38.0±1.4) weeks], the proportion of infants small for gestational age (SGA) in the CPAP treatment group was lower [0 (0/42) vs 12.3% (17/138)], and the birth weight of infants in the CPAP treatment group was bigger [(3 396±475) vs (3 082±710) g); the differences between the two groups were statistically significant (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). There were no significant differences between the CPAP treatment group and the control group in terms of delivery mode, rates of postpartum hemorrhage and preterm birth, umbilical artery blood gas analysis pH&lt;7.1, lactate≥6.0 mmol/L, base excess&lt;-12.0 mmol/L and the incidence of gestational diabetes mellitus and HDP (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). (2) The placental weight of the CPAP treatment group was significantly lower than that of the control group [(554.0±70.6) vs (615.7±119.1) g], the placental weight/newborn birth weight ratio of the CPAP treatment group was significantly lower than that of the control group (median: 0.17 vs 0.19), and the differences were statistically significant (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). (3) The incidence of HDP in pregnant women with moderate to severe OSAS in the CPAP treatment group was lower than that in the control group [1/9 vs 61.8% (21/34)], and the difference was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). &lt;b&gt;Conclusions:&lt;/b&gt; CPAP treatment could prolong the gestational age in pregnant women with OSAS, reduce the incidence of SGA, increase the birth weight of infants, and reduce the incidence of HDP in pregnant women with moderate to severe OSAS, and is worth promoting in clinical practice. The improvement of neonatal outcomes by CPAP treatment is closely related to the placenta, which is worthy of further ex","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"171-176"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The risk and perioperative management for cesarean delivery at the second stage of labor]. 第二产程剖宫产的风险及围手术期处理
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20240919-00511
L Y Li, X Y Guo, Y Wei
{"title":"[The risk and perioperative management for cesarean delivery at the second stage of labor].","authors":"L Y Li, X Y Guo, Y Wei","doi":"10.3760/cma.j.cn112141-20240919-00511","DOIUrl":"10.3760/cma.j.cn112141-20240919-00511","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"231-235"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Value of high-risk HPV viral load in cervical cancer screening and triage: a real world retrospective study based on cervical cancer screening program in Quanzhou, China]. [高危HPV病毒载量在宫颈癌筛查和分诊中的价值:基于泉州宫颈癌筛查项目的真实世界回顾性研究]。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20241210-00657
Y Q Chen, Q M Huang, M L Hong, Y Q Zhu, Y L Gao, L Y Chen, L Y Chen

Objective: To evaluate the clinical value of high-risk human papillomavirus (HPV) viral load for the cervical cancer screening and triage of high-risk HPV positive populations without additional tests. Methods: (1) This study conducted a retrospective analysis of 29 720 women aged 35-64 years who received cervical cancer screening in Quanzhou, China, in 2021. Fourteen high-risk HPV types (including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) were detected for cervical cancer primary screening using hybrid capture-chemiluminescence method. High-risk HPV positive samples were further subjected to HPV 16/18 genotyping using hybrid capture-chemiluminescence method. Among them, HPV 16/18 positive women were directly referred to colposcopy, while the other 12 high-risk HPV positive samples were further subjected to liquid based cytology test. Those with abnormal or suspicious cytology were referred to colposcopy. Biopsies were taken for histopathological examination of suspicious or abnormal individuals under colposcopy. (2) Ten cases of colposcopy loss or refusal to undergo examination were excluded, and the data from the 29 710 cases were analyzed. The HPV viral loads of the other 12 high-risk HPV positive populations were focused and evaluated their HPV viral loads for further cervical intraepithelial neoplasia (CIN) Ⅱ and above lesions (CINⅡ+) triage in cervical cancer screening. Results: (1) Among 29 720 women, 2 487 women (8.37%, 2 487/29 720) were positive for high-risk HPV, including 807 women (2.72%, 807/29 720) were positive for HPV 16/18 and 1 680 patients (5.65%, 1 680/29 720) were positive for the other 12 high-risk HPV types. Among 1 680 women who tested positive for the other 12 high-risk HPV types, 573 patients were atypical squamous cell carcinoma of unclear significance or above, 346 patients were CIN Ⅰ, 122 patients were CIN Ⅱ-Ⅲ, 9 patients were squamous cell carcinoma patients, and 4 patients were adenocarcinoma in situ. The immediate risk of CIN Ⅱ+ in HPV 16/18 positive women (11.13%) was approximately four times higher than that of other 12 high-risk HPV positive women (2.74%). (2) Through the viral load analysis of the other 12 high-risk HPV types, we found that the viral load of the other 12 high-risk HPV provide a good value for the pathological results, with a clinical cutoff (CO) value of 11.21 relative light unit/CO (RLU/CO) for the CINⅡ+ detection. Except for HPV 16/18 positive patients, when the viral load values of the other 12 high-risk HPV types were greater than 10 RLU/CO, these patients had a higher risk of CINⅡ+, with a positive predictive value of 31.29%. CINⅡ+ was not found in any of the other 12 high-risk HPV positive with viral load values less than or equal to 10 RLU/CO. Conclusions: Using hybrid capture-chemiluminescence HPV tests for HPV 16/18 genotyping, combined with the viral loads (>10 RLU/CO) of th

目的:评价高危人乳头瘤病毒(HPV)病毒载量对宫颈癌筛查和高危HPV阳性人群分诊的临床价值。方法:(1)本研究对2021年中国泉州地区接受宫颈癌筛查的29 720名35-64岁女性进行回顾性分析。采用杂交捕获-化学发光法对14种高危型HPV (HPV 16、18、31、33、35、39、45、51、52、56、58、59、66、68)进行宫颈癌初筛。高危HPV阳性样本进一步采用杂交捕获-化学发光法进行HPV 16/18基因分型。其中HPV 16/18阳性女性直接行阴道镜检查,其余12例高危HPV阳性样本进一步行液基细胞学检查。细胞学异常或可疑者行阴道镜检查。对可疑或异常个体在阴道镜下行组织病理学检查。(2)排除10例阴道镜丢失或拒绝检查的病例,对29710例病例的资料进行分析。对其他12例高危HPV阳性人群的HPV病毒载量进行关注,并评估其HPV病毒载量,以便在宫颈癌筛查中进一步进行宫颈上皮内瘤变(CIN)Ⅱ及以上病变(CINⅡ+)分诊。结果:(1)29 720例女性中高危型HPV阳性2 487例(8.37%,2 487/29 720),其中HPV 16/18型阳性807例(2.72%,807/29 720),其他12种高危型HPV阳性1 680例(5.65%,1 680/29 720)。在1 680例其他12种高危型HPV检测阳性的女性中,573例为意义不明确及以上的非典型鳞状细胞癌,346例为CINⅠ,122例为CINⅡ-Ⅲ,9例为鳞状细胞癌,4例为原位腺癌。HPV 16/18阳性女性(11.13%)发生CINⅡ+的直接风险约为其他12名高危HPV阳性女性(2.74%)的4倍。(2)通过对其他12种高危型HPV的病毒载量分析,我们发现其他12种高危型HPV的病毒载量为病理结果提供了较好的值,CINⅡ+检测的临床截止值(CO)为11.21相对光单位/CO (RLU/CO)。除HPV 16/18阳性患者外,当其他12种高危型HPV病毒载量值大于10 RLU/CO时,这些患者发生CINⅡ+的风险较高,阳性预测值为31.29%。在其他12例病毒载量小于或等于10 RLU/CO的高危HPV阳性中未发现CINⅡ+。结论:采用杂交捕获-化学发光HPV检测HPV 16/18基因分型,结合其他12例高危HPV的病毒载量(bbb10 RLU/CO)分析,可以在不进行额外检测的情况下对HPV阳性人群进行分类。这种分诊策略可以促进宫颈癌筛查的覆盖率,特别是在细胞学病理学家或经济资源有限的地方。
{"title":"[Value of high-risk HPV viral load in cervical cancer screening and triage: a real world retrospective study based on cervical cancer screening program in Quanzhou, China].","authors":"Y Q Chen, Q M Huang, M L Hong, Y Q Zhu, Y L Gao, L Y Chen, L Y Chen","doi":"10.3760/cma.j.cn112141-20241210-00657","DOIUrl":"10.3760/cma.j.cn112141-20241210-00657","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the clinical value of high-risk human papillomavirus (HPV) viral load for the cervical cancer screening and triage of high-risk HPV positive populations without additional tests. <b>Methods:</b> (1) This study conducted a retrospective analysis of 29 720 women aged 35-64 years who received cervical cancer screening in Quanzhou, China, in 2021. Fourteen high-risk HPV types (including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) were detected for cervical cancer primary screening using hybrid capture-chemiluminescence method. High-risk HPV positive samples were further subjected to HPV 16/18 genotyping using hybrid capture-chemiluminescence method. Among them, HPV 16/18 positive women were directly referred to colposcopy, while the other 12 high-risk HPV positive samples were further subjected to liquid based cytology test. Those with abnormal or suspicious cytology were referred to colposcopy. Biopsies were taken for histopathological examination of suspicious or abnormal individuals under colposcopy. (2) Ten cases of colposcopy loss or refusal to undergo examination were excluded, and the data from the 29 710 cases were analyzed. The HPV viral loads of the other 12 high-risk HPV positive populations were focused and evaluated their HPV viral loads for further cervical intraepithelial neoplasia (CIN) Ⅱ and above lesions (CINⅡ<sup>+</sup>) triage in cervical cancer screening. <b>Results:</b> (1) Among 29 720 women, 2 487 women (8.37%, 2 487/29 720) were positive for high-risk HPV, including 807 women (2.72%, 807/29 720) were positive for HPV 16/18 and 1 680 patients (5.65%, 1 680/29 720) were positive for the other 12 high-risk HPV types. Among 1 680 women who tested positive for the other 12 high-risk HPV types, 573 patients were atypical squamous cell carcinoma of unclear significance or above, 346 patients were CIN Ⅰ, 122 patients were CIN Ⅱ-Ⅲ, 9 patients were squamous cell carcinoma patients, and 4 patients were adenocarcinoma in situ. The immediate risk of CIN Ⅱ<sup>+</sup> in HPV 16/18 positive women (11.13%) was approximately four times higher than that of other 12 high-risk HPV positive women (2.74%). (2) Through the viral load analysis of the other 12 high-risk HPV types, we found that the viral load of the other 12 high-risk HPV provide a good value for the pathological results, with a clinical cutoff (CO) value of 11.21 relative light unit/CO (RLU/CO) for the CINⅡ<sup>+</sup> detection. Except for HPV 16/18 positive patients, when the viral load values of the other 12 high-risk HPV types were greater than 10 RLU/CO, these patients had a higher risk of CINⅡ<sup>+</sup>, with a positive predictive value of 31.29%. CINⅡ<sup>+</sup> was not found in any of the other 12 high-risk HPV positive with viral load values less than or equal to 10 RLU/CO. <b>Conclusions:</b> Using hybrid capture-chemiluminescence HPV tests for HPV 16/18 genotyping, combined with the viral loads (>10 RLU/CO) of th","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"193-201"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Short-term efficacy of mid-urethral sling with autologous fascia lata sling in the treatment of stress urinary incontinence]. 【尿道中悬吊联合自体阔筋膜悬吊治疗应激性尿失禁的近期疗效观察】。
Pub Date : 2025-03-25 DOI: 10.3760/cma.j.cn112141-20240921-00515
Y Q Guan, J F Yang, J S Han, Y T Wang, K Zhang, Y Yao, B Yu

Objective: To observe the safety and short-term efficacy of using an autologous fascia lata sling (AFLS) for tension-free mid-urethral sling (MUS) in the treatment of stress urinary incontinence (SUI). Methods: Between February 2022 and December 2023, 11 patients with SUI underwent AFLS-MUS. Preoperative data were recorded, including basic patient information and completion of urinary distress inventory 6 (UDI-6). During surgery, AFLS was harvested through a small incision using a tendon extractor, and used as a sling for transobturator or retropubic MUS. Perioperative indicators were recorded, including surgical approach, operation time, intraoperative blood loss, postoperative hospital stay, duration of catheterization, perioperative complications (Clavien-Dindo classification), and surgical costs. Follow-ups included outpatient physical examination at 2 months postoperatively, and telephone follow-up at 6 months, 1 year, and annually thereafter. Follow-up content included the presence or absence of urinary leakage symptoms, UDI-6, satisfaction, patient global impression of improvement (PGI-I), and complications. Results: The age of the 11 patients was (54.8±10.9) years (range: 41-72 years), with body mass index of (23.9±1.8) kg/m² (range: 21.4-27.3 kg/m²). All patients experienced urinary leakage after coughing, sneezing and physical activity, with positive SUI provocation tests. The preoperative UDI-6 was 50.0±21.6 (range: 16.7-79.2), the result of 1-hour pad test was (18.9±12.0) g (range: 2.5-71.2 g). Four cases underwent MUS only, with operation time of (98.0±13.3) minutes (range: 86-117 minutes), and intraoperative blood loss of (17.5±5.0) ml (range: 10-20 ml); 7 cases also underwent pelvic floor repair simultaneously. The postoperative hospital stay was (3.5±2.0) days (range: 2-9 days). The duration of catheterization was (4.5±3.8) days (range: 2-11 days), with postoperative urinary retention in three cases, one of which underwent sling release surgery due to severe postoperative voiding difficulty 1 week after MUS, with no other complications of Clavien-Dindo grade 2 or above. The cost of AFLS harvest plus MUS was (2 762±293) yuan. At the 2-month outpatient follow-up, all patients were free of urinary leakage symptoms, with UDI-6 of 2.3±1.9 (range: 0-8.3); satisfaction was "very satisfied" in 10 cases and "fairly satisfied" in 1 case, with PGI-I all being "much better", and pelvic examinations were normal. Telephone follow-up showed one case lost to follow-up, and the remaining 10 cases had follow-up time of (18.6±4.9) months (range: 7-26 months), all without urinary leakage, with UDI-6 of 2.7±2.6, satisfaction rated as "very satisfied", and PGI-I all "much better". Conclusion: This modified AFLS-MUS for the treatment of SUI shows good short-term efficacy and high safety in harvest site, with the need for more data accumulation and long-term follow-up.

目的观察在治疗压力性尿失禁(SUI)时使用自体筋膜拉塔吊带(AFLS)进行无张力尿道中段吊带(MUS)的安全性和短期疗效。方法:2022年2月至2023年12月期间,11名SUI患者接受了AFLS-MUS手术。记录术前数据,包括患者基本信息和尿窘迫量表 6(UDI-6)的完成情况。手术期间,使用肌腱提取器通过小切口提取 AFLS,并将其用作经尿道或耻骨后 MUS 的吊带。围手术期指标均有记录,包括手术方式、手术时间、术中失血量、术后住院时间、导尿时间、围手术期并发症(Clavien-Dindo分类)和手术费用。随访包括术后 2 个月的门诊体检,以及术后 6 个月、1 年和以后每年的电话随访。随访内容包括有无漏尿症状、UDI-6、满意度、患者总体改善印象(PGI-I)和并发症。结果:11 名患者的年龄为 (54.8±10.9) 岁(范围:41-72 岁),体重指数为 (23.9±1.8) kg/m²(范围:21.4-27.3 kg/m²)。所有患者在咳嗽、打喷嚏和体力活动后都会出现漏尿,SUI激发试验均呈阳性。术前 UDI-6 为 50.0±21.6(范围:16.7-79.2),1 小时尿垫测试结果为(18.9±12.0)克(范围:2.5-71.2 克)。4例仅行MUS,手术时间为(98.0±13.3)分钟(范围:86-117分钟),术中失血量为(17.5±5.0)毫升(范围:10-20毫升);7例同时行盆底修复术。术后住院时间为(3.5±2.0)天(范围:2-9天)。导尿时间为(4.5±3.8)天(范围:2-11 天),3 例患者术后出现尿潴留,其中 1 例患者在 MUS 术后 1 周因术后严重排尿困难而接受了吊带松解手术,无其他 Clavien-Dindo 2 级或以上并发症。AFLS采集加MUS的费用为(2 762±293)元。2 个月门诊随访时,所有患者均无漏尿症状,UDI-6 为 2.3±1.9(范围:0-8.3);满意度 10 例为 "非常满意",1 例为 "比较满意",PGI-I 均为 "好多了",盆腔检查正常。电话随访结果显示,1 例患者失去了随访机会,其余 10 例患者的随访时间为(18.6±4.9)个月(范围:7-26 个月),均无漏尿,UDI-6 为 2.7±2.6,满意度为 "非常满意",PGI-I 均为 "好多了"。结论这种改良的 AFLS-MUS 用于治疗 SUI 显示出良好的短期疗效和较高的安全性,但还需要更多的数据积累和长期随访。
{"title":"[Short-term efficacy of mid-urethral sling with autologous fascia lata sling in the treatment of stress urinary incontinence].","authors":"Y Q Guan, J F Yang, J S Han, Y T Wang, K Zhang, Y Yao, B Yu","doi":"10.3760/cma.j.cn112141-20240921-00515","DOIUrl":"10.3760/cma.j.cn112141-20240921-00515","url":null,"abstract":"<p><p><b>Objective:</b> To observe the safety and short-term efficacy of using an autologous fascia lata sling (AFLS) for tension-free mid-urethral sling (MUS) in the treatment of stress urinary incontinence (SUI). <b>Methods:</b> Between February 2022 and December 2023, 11 patients with SUI underwent AFLS-MUS. Preoperative data were recorded, including basic patient information and completion of urinary distress inventory 6 (UDI-6). During surgery, AFLS was harvested through a small incision using a tendon extractor, and used as a sling for transobturator or retropubic MUS. Perioperative indicators were recorded, including surgical approach, operation time, intraoperative blood loss, postoperative hospital stay, duration of catheterization, perioperative complications (Clavien-Dindo classification), and surgical costs. Follow-ups included outpatient physical examination at 2 months postoperatively, and telephone follow-up at 6 months, 1 year, and annually thereafter. Follow-up content included the presence or absence of urinary leakage symptoms, UDI-6, satisfaction, patient global impression of improvement (PGI-I), and complications. <b>Results:</b> The age of the 11 patients was (54.8±10.9) years (range: 41-72 years), with body mass index of (23.9±1.8) kg/m² (range: 21.4-27.3 kg/m²). All patients experienced urinary leakage after coughing, sneezing and physical activity, with positive SUI provocation tests. The preoperative UDI-6 was 50.0±21.6 (range: 16.7-79.2), the result of 1-hour pad test was (18.9±12.0) g (range: 2.5-71.2 g). Four cases underwent MUS only, with operation time of (98.0±13.3) minutes (range: 86-117 minutes), and intraoperative blood loss of (17.5±5.0) ml (range: 10-20 ml); 7 cases also underwent pelvic floor repair simultaneously. The postoperative hospital stay was (3.5±2.0) days (range: 2-9 days). The duration of catheterization was (4.5±3.8) days (range: 2-11 days), with postoperative urinary retention in three cases, one of which underwent sling release surgery due to severe postoperative voiding difficulty 1 week after MUS, with no other complications of Clavien-Dindo grade 2 or above. The cost of AFLS harvest plus MUS was (2 762±293) yuan. At the 2-month outpatient follow-up, all patients were free of urinary leakage symptoms, with UDI-6 of 2.3±1.9 (range: 0-8.3); satisfaction was \"very satisfied\" in 10 cases and \"fairly satisfied\" in 1 case, with PGI-I all being \"much better\", and pelvic examinations were normal. Telephone follow-up showed one case lost to follow-up, and the remaining 10 cases had follow-up time of (18.6±4.9) months (range: 7-26 months), all without urinary leakage, with UDI-6 of 2.7±2.6, satisfaction rated as \"very satisfied\", and PGI-I all \"much better\". <b>Conclusion:</b> This modified AFLS-MUS for the treatment of SUI shows good short-term efficacy and high safety in harvest site, with the need for more data accumulation and long-term follow-up.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 3","pages":"177-182"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华妇产科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1